Kaiser Health News
In this episode of KHN’s “What the Health?” Sarah Jane Tribble of Kaiser Health News, Joanne Kenen of Politico, Margot Sanger-Katz of The New York Times and Paige Winfield Cunningham of The Washington Post examine how even after Republicans failed to repeal and replace the Affordable Care Act, the health care debate continues to roil politics. They discuss how Republicans in Congress have shifted their ACA messaging and how the Democrats are looking to Medicare expansion. They also discuss state efforts to expand Medicaid and drug pricing. And they spend a moment talking about Congress’ push to do something about the opioid crisis.
Editorial pages focus on these and other health topics.
Each week, KHN's Shefali Luthra finds interesting reads from around the Web.
Media outlets report on news from D.C., California, Texas, Iowa, Louisiana, Wisconsin, Florida, Puerto Rico, Georgia, Ohio, Arizona, Minnesota and Illinois.
Scientists have figured out a way to make cells turn dark like a tattoo when calcium levels in the blood is too high. In other public health news: gene therapy, concussions, categorizing sounds, homeopathic remedies, and autism.
Touted as a "breakthrough" discovery, a new paper challenges the traditional belief that keeping the liver cool while transporting it from donor to recipient will slow the dying process.
Early detection is key, researchers say, and spouses play an important role by spotting unusual looking moles and encouraging visits to dermatologists.
The lag it takes to get back on Medicaid can mean relapses or other serious problems for prisoners struggling with addiction or mental health issues. "On the outside, if they didn't get their treatment, they'd come right back through the front door again," New Hampshire Department of Corrections Superintendent David Dionne says.
The Justice Department’s antitrust chief, Makan Delrahim, has taken a tough stand against similar types of deals in the past.
Drugmakers are expecting to take a financial hit from the copay accumulator programs that PBMs have begun marketing. And the Supreme Court may review a whistleblower case that could have implications across the pharmaceutical industry.